Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Go back to Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)| (NASDAQ: INTS) | Delayed: 4.11 +0.23 (5.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.88 | 52 Week High | $ | |||
| Open | $3.79 | 52 Week Low | $ | |||
| Day High | $4.29 | P/E | N/A | |||
| Day Low | $3.79 | EPS | $ | |||
| Volume | 45,148 | |||||
